




FIG. 1A




FIG. 1B

Dectin-1 ab Clone	HEK-Blue hDectin-1a cells EC50 (nM)	HEK-Blue hDectin-1b cells EC50 (nM)	HEK293F hDectin- 1a FL EC50 (nM)	Human monocytes EC50 (nM)	Cynomolgus monkey monocytes EC50 (nM)
2M24	0.4	1	1.1	0.3	0.3
2M08	2.6	>190	1.9	>190	N/A
2M12	16.9	>142	2.8	>142	N/A
2M38	4.5	>96	6.1	>96	N/A
2M49	>169	>169	>169	>169	N/A
15E2	1.2	9.3	1.4	0.6	14
259931	0.8	0.9	1.2	0.3	16.5
GE2	1.9	12	2.4	1.4	N/A

FIG. 1C




FIG. 2A





FIG. 2B






FIG. 4




FIG. 5A




FIG. 5B

Cytokine secretion of Dectin-1 agonist Ab (15E2) in solution in cultured human primary monocytes




FIG. 6A

Cytokine secretion of Dectin-1 agonist Ab (15E2) in solution in cultured human primary macrophages




FIG. 6B

Cytokine secretion of immobilized Dectin-1 agonist Ab in cultured human primary monocytes




FIG. 7A

Cytokine secretion of immobilized Dectin-1 agonist Ab in cultured human primary PBMCs




FIG. 7B




FIG. 8

Dectin-1 antibody Clone	HEK-Blue hDectin-1a cells EC50 (nM)	HEK-Blue hDectin-1b cells EC50 (nM)	HEK293F hDectin-1a FL EC50 (nM))	Human monocytes EC50 (nM)	Competitive on with natural ligands	TNFα secretion in PBMC (fold change to isotype)	IL6 secretion in PBMC (fold change to isotype)	IFNγ secretion in PBMC (fold change to isotype)	Phagocytosis
2M24	0.4	1	1.1	0.3	NO	19	6.4	4.1	YES
15E2	1.2	9.3	1.4	0.6	YES	3	2.6	1.6	YES

FIG. 9




FIG. 10B





FIG. 10A

17/104
FIG. 11A



Targets for Oncology	
CD70	
HER2	
DLL3	
NECTIN-4	
TROP-2	
MESOTHELIN	
LIV-1	
C-MET	
FOLR1	
EGFR	

FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13

Coupling Dectin-1-expressing HEK293 cells and Raji cells




FIG. 14A

Coupling human M0 macrophages and Raji cells




FIG. 14B

23/104




FIG. 15




FIG. 16




FIG. 17




FIG. 18

Coupling of Fab 2M24-mSA or 2M24-mSA to
biotinylated target antibodies




FIG. 19B

Chimeric fusions of monomeric Streptavidin (mSA) and
Fab 2M24 or full length 2M24







FIG. 19A

28/104






FIG. 21A




FIG. 21B




FIG. 22A




FIG. 22C




FIG. 22B






FIG. 22D



Chimeric Dectin-1 antibody (or Fab) fused to an amyloid-reactive peptide (p5+14) for targeted phagocytosis of amyloid fibrils



Bispecific antibody that binds to Dectin-1 and Serum Amyloid protein P (SAP) for targeted phagocytosis of amyloid fibrils




FIG. 24




FIG. 25A

Targets identified by proteomics studies	Targets identified by RNA sequencing of mastocytosis patients samples
MRGPRX2	CD33 (SIGLEC 3)
CD171 (L1CAM)	CD25 (IL25Ra)
SIGLEC 6	CD30 (TNFRFS8)
CD117	SIGLEC 8
CD203c	CD13
CD51	CD44
DPP4	CD52
	CD117
	CD123

FIG. 25B





FIG. 26

Bispecific(anti-Dectin-1/anti-microbialtarget) against bacteria, viruses, and fungi



Dectin-1 bispecific antibodies deploys Dectin-1-expressing phagocytes to eliminate bacterial, viral or fungal pathogens




FIG. 27




FIG. 28A




FIG. 28B

39/104




FIG. 29A

40/104




FIG. 29B




FIG. 30

42/104





FIG. 31A







FIG. 31C

45/104

**FIG. 32A**




FIG. 32B




FIG. 33A

48/104




FIG. 33B




FIG. 34A

50/104




FIG. 34B

51/104




FIG. 35A

52/104




FIG. 35B

53/104




FIG. 36A

54/104




FIG. 36B

55/104




FIG. 37A

56/104




FIG. 37B

57/104




FIG. 38

58/104




FIG. 39A

59/104




FIG. 39B

60/104




FIG. 40A

61/104




FIG. 40B

62/104





FIG. 40C






FIG. 42




FIG. 43




FIG. 44

67/104




FIG. 45




FIG. 46

69/104





FIG. 47

70/104






FIG. 48

71/104



72/104



73/104




FIG. 50

74/104





FIG. 51

75/104



Time (min)

FIG. 52A

76/104




FIG. 52B

77/104




FIG. 52C

78/104




FIG. 53A




FIG. 53B




FIG. 53C




FIG. 54




FIG. 55A

82/104




FIG. 55B

83/104




FIG. 55C




FIG. 55D




FIG. 56A




FIG. 56B




FIG. 57A

87/104




FIG. 57B




FIG. 58

89/104




FIG. 59A




FIG. 59B




FIG. 59C

92/104




FIG. 59E




FIG. 59D

93/104




FIG. 60A




FIG. 60B




FIG. 61A




FIG. 61B

97/104





FIG. 62




FIG. 63




FIG. 64A




FIG. 64B




FIG. 65A




FIG. 65B




FIG. 65C




FIG. 66